Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Although the importance of palliative care in pediatric patients has been emphasized, many health care providers have difficulty determining when patients should be referred to the palliative care team. The Paediatric Palliative Screening Scale (PaPaS) was developed as a tool for screening pediatric patients for palliative care needs. The study aimed to evaluate the PaPaS as a reliable tool for primary care clinicians unfamiliar with palliative care.
Methods: This was a retrospective cohort study of patients referred to the pediatric palliative care teams in two tertiary hospitals in the Republic of Korea between July 2018 and October 2019.
Results: The primary clinical and pediatric palliative care teams assessed the PaPaS scores of 109 patients, and both teams reported a good agreement for the sum of the PaPaS score. Furthermore, the PaPaS scores correlated with those obtained using the Lansky performance scale. Although the mean PaPaS score was higher in the pediatric palliative care team, the scores were higher than the cut-off score for referral in both groups.
Conclusion: The PaPaS can be a useful tool for primary care clinicians to assess the palliative care needs of patients and their families.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146205 | PMC |
| http://dx.doi.org/10.1186/s12904-021-00765-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How to distinguish opioid toxicity from natural dying in patients with advanced illness and how to manage opioid toxicity.
Clin Med (Lond)
September 2025
Hull University Teaching Hospitals NHS Trust, Castle Rd, Cottingham HU16 5JQ, UK.
Patients with advanced, life limiting illness might develop pain or breathlessness, requiring opioids. Opioid neurotoxicities, like sedation and delirium, overlap with signs of natural dying. Understanding natural dying is a core clinical skill for all health care professionals.
View Article and Find Full Text PDFEfficacy of Virtual Reality in Managing Pain for Patients in Palliative Care: A Systematic Review and Meta-Analysis.
J Pain Symptom Manage
September 2025
School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
Background: Pain management in palliative care, especially among cancer patients, remains a critical challenge that significantly affects patient quality of life. Virtual Reality (VR) has emerged as a promising non-pharmacological intervention that could revolutionize pain management strategies in this vulnerable population. This systematic review and meta-analysis evaluate the effectiveness of VR interventions, focusing exclusively on randomized controlled trials to provide a comprehensive assessment of VR as a therapeutic tool.
View Article and Find Full Text PDFPerineural botulinum toxin in the management of post-traumatic headache: a case report.
Rev Esp Anestesiol Reanim (Engl Ed)
September 2025
Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.
Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).
View Article and Find Full Text PDFWhere comfort and nutrition meet: A case series of children with severe neurologic impairment receiving home parenteral nutrition at the end of life.
Nutr Clin Pract
September 2025
Department of Pediatrics, Mayo Clinic, Rochester, Minnesota, USA.
Home parenteral nutrition (HPN) is a life-sustaining therapy traditionally used as a bridge to enteral autonomy or intestinal transplantation. Increasingly, it is used for intractable feeding intolerance (IFI), which can occur near the end of life (EOL) in children with severe neurological impairment (SNI). In these cases, HPN use differs from its historical role and requires tailored outpatient planning.
View Article and Find Full Text PDFEstimating Health State Utilities for IDH-Mutant Diffuse Glioma.
Pharmacoecon Open
September 2025
Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.
View Article and Find Full Text PDF